By Chris Wack
BioCryst Pharmaceuticals shares were down 12% to $8.08 after the company reported a fourth-quarter loss that was wider than expected.
The stock hit its 52-week high of $9.50 Friday, and is up 42% in the past 12 months.
The biotechnology company said it had a quarterly loss of $26.8 million, or 13 cents a share, compared with a loss of $61.7 million, or 31 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $13 million, or five cents a share.
Revenue for the quarter was $131.5 million, compared with last year's $93.4 million and the $130.1 million analysts were expecting.
The company said quarterly revenue for Orladeyo, its treatment for the prevention of hereditary angioedema attacks, was $124.2 million, 36.6% higher than last year.
BioCryst increased its 2025 revenue guidance for Orladeyo to $535 million to $550 million, from its previous estimate of $515 million to $535 million.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 24, 2025 10:59 ET (15:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.